US Procedures Slow to 10%, but 546 Placements and a Smaller-Than-Feared Price Cut Carry the Quarter: Maintaining Outperform, Base Case Raised to $510

Results vs. Consensus

In July, the scorecard and the tape pointed in opposite directions. This quarter the scorecard did most of the talking. Both headline lines beat their consensus: revenue by 4.8% and non-GAAP EPS by 13.2%. The one number that did not improve was the one the stock trades on. US da Vinci procedure growth slowed to 10% from 12% in Q2 and 14% in Q1. Management had warned in July that Q3 carried the year's toughest US comparison, and it said the result was consistent with that warning. The opening print in the reaction session agreed with the bears; the close agreed with management.

Q3 2026 Scorecard

We found consensus from two independent sources only for revenue and EPS. We grade procedures and margins against management's own July framing instead.

Year-over-Year Comparison (Q3 2026 vs. Q3 2025)

Sequential Comparison (Q3 2026 vs. Q2 2026)

Revenue

Revenue grew 21.7% to $3,048.7M against total procedure growth (da Vinci plus Ion) of 15%. That seven-point gap is Intuitive's innovation-led model at work: da Vinci 5, SP and Ion carry richer instrument and service content, and system placements grew faster than procedures. Recurring revenue was 84% of the total. By line, systems revenue (+30.3%) led, followed by services (+21.8%) and I&A (+18.3%). By geography, OUS revenue grew 25.2% to $985.7M and US revenue grew 20.1% to $2,063.0M. US I&A revenue rose 17.5%, well ahead of the 10% growth in US da Vinci procedures. That gap likely reflects Ion (US Ion procedures +29%), US SP (+50%) and da Vinci 5-specific instruments. It also shows that a slower US procedure line has not yet slowed US recurring revenue at the same rate. Revenue includes the da Vinci and Ion distribution businesses in Italy, Spain and Portugal, acquired on March 1 for ~$533M. The move to direct sales in those markets should lift OUS revenue per procedure this year.

Margins

Reported non-GAAP gross margin of 69.9% included the $27.8M tariff refund. Excluding it, the margin was 68.9%, up 90bp year-over-year and 20bp above Q2's comparable 68.7%, on product cost reductions and fixed-overhead leverage. That held even as systems, a lower-margin line than I&A, grew faster than the rest of the business. Non-GAAP operating expenses rose 18.1% to $859.9M on variable compensation, headcount and prototype spending, the fastest growth this year. Management said part of the increase reflected timing between quarters. GAAP R&D rose 24.0%, against 11.2% for GAAP SG&A excluding litigation charges. Non-GAAP operating margin still expanded about 270bp to 41.6%. The GAAP picture differs: the $450M antitrust settlement sits in SG&A, and GAAP operating income fell 22.0% to $592.6M.

EPS

Non-GAAP EPS of $3.00 grew 25.0% (22.5% on the clean $2.94). It ran ahead of revenue on three lines. Operating leverage contributed most: non-GAAP operating income grew 30.1%. A 21.4% non-GAAP tax rate, slightly below the ~22% run-rate, helped at the margin. The diluted share count fell 2.8% to 351.6M. Partly offsetting, non-GAAP other income fell to $75M from $83M in Q2, because $2.94B of buybacks reduced the cash balance. The share count effect will be larger in Q4. Repurchases were concentrated in July and August, so the Q3 average share count captured only part of the 7.8M shares retired. GAAP EPS of $1.49 fell 23.6%. The decline reflected the litigation settlement, which cost $347M after tax, or $0.99 per share, and should not recur.

Segment Performance

Revenue by Line and Geography — Q3 2026

Platform and Placement Mix — Q3 2026

da Vinci Placements by Region — Q3 2026

Instruments & Accessories — $1,797.4M (+18.3%)

I&A is the recurring core: 59% of revenue, tied directly to procedure volume. It grew 18.3% on 14% da Vinci procedure growth and 31% Ion growth. da Vinci I&A revenue per procedure was ~$1,860, against ~$1,800 a year ago and ~$1,830 in Q2. SP and da Vinci 5-specific instruments drove the increase, and procedure mix partly offset it, with cholecystectomy and other lower-content benign general surgery growing fastest. The number to watch from here is that per-procedure figure. In 2027 it will absorb the 3-5% pricing actions before the mix offsets.

"Da Vinci I&A revenue per procedure was approximately $1,860 compared to $1,800 last year, primarily driven by higher SP procedures and da Vinci 5 specific I&A, partially offset by procedure mix." — Jamie Samath, CFO

Assessment: I&A per procedure rose 3% even as the procedure mix shifted toward lower-content benign cases. That is the mix engine the 2027 pricing math relies on. If da Vinci 5, SP and Force Feedback can add ~3% a year on their own, a 3-5% pricing reset phased over 2027 leaves I&A per procedure roughly flat rather than in decline. We model it flat.

Systems — $769.1M (+30.3%); 546 Placements (+28%)

Capital carried the quarter. Placements by model were 315 da Vinci 5, 87 Xi, 65 XiR, 42 SP and 37 X. US placements rose 27% to 335 on more multisystem deals. OUS placements rose 29% to 211, with Europe up 83% to 115. Only 150 placements involved trade-ins, against 141 a year ago. Placements net of trade-ins therefore rose ~40% in management's count (396 against 286 on our trade-in arithmetic, +38%), and US net placements rose 41%. Operating leases were 53% of placements, against 54% a year ago. Usage-based leases rose to 160 from 115. The purchased-system ASP held at ~$1.6M: the da Vinci 5 mix lifted it and a higher XiR mix offset that. Purchased ASPs were about $1.2M for XiR and $0.5M for X.

"In Q3, global customer demand across our da Vinci portfolio remains strong. Da Vinci system placements increased 28% worldwide with da Vinci 5 and SP accounting for 65% of global placements." — David Rosa, CEO

Assessment: In Q2, almost all of the US placement growth came from trade-ins. The da Vinci 5 upgrade cycle was the story, and the bear could argue that hospitals were swapping machines, not adding capacity. Q3 answers that argument. Trade-ins were nearly flat while placements grew 28%. A hospital that adds a system adds capacity it expects to fill, so this is the best leading indicator for 2027 US procedures in the print. The quarter does not prove that US growth reaccelerates, but it is the evidence most at odds with a structural-maturation story.

Services — $482.2M (+21.8%)

Service revenue grew 21.8% on a 12% larger da Vinci installed base and a 21% larger Ion base. The growth gap reflects a higher mix of da Vinci 5 systems. Together with I&A and the operating-lease revenue inside Systems, services make up the 84% of revenue that is recurring.

Assessment: Services is the quietest line and the most predictable. It grows with the installed base plus a mix premium. With more than 2,000 da Vinci 5 systems now installed, the premium compounds even if the procedure line slows.

OUS — Procedures +20%, Placements +29%, Benign +41%

Outside the US, da Vinci procedures grew 20%: Europe +20%, Asia +19% and Rest of World +22%. The UK, Germany, Italy, India and Taiwan led. Japan's growth accelerated on early response to the June reimbursement changes. Korea slowed against a prior-year recovery from physician strikes, and China grew only in line with the corporate average after fewer placements in recent quarters. Benign OUS procedures, now more than a quarter of international volume, accelerated again, to 41% from 37% in Q2 and 34% in Q1. India grew 42% and passed 200,000 cumulative da Vinci procedures.

"Within OUS results, da Vinci adoption for benign procedures continued to accelerate, growing 41% in Q3, up from 37% in Q2 and 34% in Q1 with the strongest growth in hernia repair and cholecystectomy." — Jamie Samath, CFO

Assessment: OUS is where the 2027 pricing actions are aimed, and it is the part of the business with momentum. A benign OUS curve that has steepened two quarters in a row is the volume the price cuts are meant to unlock. If the elasticity shows up, it should show up here first.

da Vinci SP — Procedures +55%; Record 42 Placements

SP procedures grew 55%, with US growth accelerating to 50% and Korea, the largest SP market, growing 40%. In the 25 markets other than the US and Korea, SP procedures nearly doubled. Intuitive placed a record 42 SP systems (21 US, 12 Korea), and the installed base rose 42% to 487 systems in 27 countries. Adoption of the SP stapler broadened, and a US submission for the SP vessel sealer is planned for Q4.

"And in Q4, we plan to make a U.S. submission for the SP vessel sealer, which we believe is a key enabler for wider adoption of our SP platform." — David Rosa, CEO

Assessment: SP carries higher I&A per procedure than multiport and grows four times as fast, so it is one of the three offsets to the 2027 price cut. The vessel sealer is the next unlock, as the stapler was in H1.

Ion — ~49,700 Procedures (+31%); Installed Base 1,152 (+21%)

Ion procedures grew 31% to about 49,700, with US growth of 29%. Intuitive placed 56 systems (44 US, 12 OUS) against 50 a year ago, and Korea granted reimbursement in the quarter. The two development programs, on-site cytology (ROSE) and integrated endobronchial ultrasound, are both designed to add revenue per case.

Assessment: Ion growth slowed from 36% in Q2, but at 31% it still grows more than twice as fast as the core. The case for Ion is now international reimbursement, built country by country, plus higher revenue per case from ROSE and EBUS.

Key KPIs

Guidance & Outlook

The procedure guide moved in both directions: the low end rose 50bp and the high end fell 50bp, and the expectation to land near the midpoint was repeated word for word. The profitability guide moved up again. The gross-margin range rose to 68.7-69.3% from 68-69%, and the tariff drag inside it eased to ~90bp. Management named the forces on the range: faster growth of newer products in da Vinci 5 and Ion, partly offset by product cost reductions, with freight and semiconductor memory costs rising. The operating expense range was left at 11-13%, with R&D still growing faster than SG&A and no Intuitive Foundation contribution in 2026 against $70M in Q4 2025.

"We are narrowing our forecast to be within a range of 14% to 15% with an expectation to be closer to the midpoint." — Daniel Connally, Head of Investor Relations

What the guide implies for Q4: Nine-month da Vinci procedures grew ~14.6% (2,642K against 2,305K). Against a 2025 base of more than 3.1M procedures, the 14.5% midpoint implies Q4 growth of roughly 14%, the same as Q3. The 14% floor implies roughly 12% and the 15% ceiling roughly 16%. The US comparison eases slightly, to 15% from Q3's 16%. If the two-year US stack holds near 26%, US growth would be about 11% in Q4. On operating expenses, 11-13% growth on the FY2025 non-GAAP base of $3,039.2M puts Q4 at $905-966M. That is 4-11% above Q4 2025's $871.7M, or 13-21% above it once the $70M foundation contribution is removed from the base. Non-GAAP other income of $300-310M less ~$243M in the first nine months leaves $57-67M for Q4. On our ~$3.33B Q4 revenue estimate, the gross-margin midpoint implies a Q4 margin of ~68.4%, below Q3's 68.9% ex-refund. Q4 has the heaviest systems mix of the year, so that is not unreasonable, but it leaves room above the midpoint.

Our Q4 estimate: revenue ~$3.33B (+16%), non-GAAP gross margin ~68.6%, operating expenses ~$936M, and EPS ~$3.16 on ~347.5M diluted shares. That takes FY26 non-GAAP EPS to $11.40-11.50, including $0.14 of tariff refunds booked through Q3.

Guidance style: Conservative, as usual. A 4.8% revenue beat produced no change to the procedure midpoint. The pattern from Q1 has not returned in full on procedures, but it has on margin: the gross-margin range has now been raised three times. Intuitive does not guide revenue or EPS, and it said it will set 2027 operating expenses in January.

Key Topics & Management Commentary

Overall Management Tone: More assertive than in July. Management presented the pricing actions as strategy rather than concession, and it led the US discussion with the comparison instead of an apology. It was confident and specific on capital, OUS and the pipeline. It was firm but deliberately open-ended on the two items that matter most for 2027: how fast the US procedure line recovers, and how much of today's operating-margin cushion it intends to reinvest.

1. Grading the Q2 Commitments

In July we set six items to check against this quarter. Three were delivered or beat expectations, one was mixed, and two moved against us.

Assessment: The two items that drove July's sell-off went in opposite directions. The price cut came in smaller than we and the Street feared. US procedures did not recover. The capital data, however, argue that customers are building for the volume that management says is deferred, not lost.

2. US Procedures at 10%: The Comparison, the Stack, and the Watch List

US da Vinci procedures grew 10% to about 559,000, a rate one questioner called the lowest since COVID. The 10-Q attributes the growth mainly to general surgery (cholecystectomy, hernia repair, appendectomy) and to gynecology. A low double-digit decline in US bariatric procedures, about 2% of worldwide da Vinci volume, offset part of it, and the 10-Q says management believes the expiration of enhanced ACA subsidies also modestly hurt US growth. After-hours procedures and benign gynecology other than hysterectomy led growth, and da Vinci 5 now carries more than a quarter of US procedures, up from 13% a year ago.

"U.S. da Vinci growth of 10% was consistent with the expectations we described in July and reflects in part the 16% growth in the prior year quarter, our most difficult comparison of the year." — Jamie Samath, CFO

The comparison argument holds up on the numbers. US growth was 14% in Q2 2025 and 16% in Q3 2025, so both Q2 2026 (12%) and Q3 2026 (10%) sum to about 26% over two years. The watch list grew, though. Management added Medicaid eligibility changes and potential 340B changes to ACA enrollment as near-term risks.

"In the short term, we continue to monitor the impacts from lower ACA enrollment, changes to Medicaid eligibility and potential changes to 340B." — Jamie Samath, CFO

Assessment: The US line is decelerating on a reported basis and steady on a stacked basis, and the two readings will not separate until Q4 and Q1. We read 10% as the trough comparison rather than the new trend, for three reasons: the stack is flat, US net placements rose 41%, and the bariatric drag is a known, shrinking base. That view is not proven. A Q4 print below 10% on an easier comparison would break it.

3. The Price Cut, Quantified: 3-5% and Phased Through 2027

The July overhang now has a number. From H1 2027, Intuitive will extend the useful lives of a subset of core EndoWrist instruments on its fourth- and fifth-generation platforms and introduce volume-based pricing, both aimed at high-volume benign procedures. Separately, a policy-driven charge-code change in China will cut I&A prices there significantly from November. Together, management expects da Vinci I&A revenue per procedure to fall 3-5% on a mix-constant basis once the program is fully in place.

"Today, we are also quantifying the instrument pricing actions we discussed in July, which we expect to reduce da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis once fully implemented." — Jamie Samath, CFO

"For reference, that is less than the 7% we estimated when we launched our first extended use program in 2020." — Jamie Samath, CFO

Three details matter for the model. The figure excludes the accretive mix drivers (Force Feedback, da Vinci 5 and SP), which management expects to keep growing faster than base I&A. The US extended-use instruments still need 510(k) clearance, with rollout from late Q1, Europe in H2 and full effect not until year-end 2027. And management expects only a modest gross-margin effect, which cost reductions should offset during 2027.

Assessment: In July we wrote that the Street would model the headwind at the bearish end of a 5-7 point range until it was quantified. The quantified figure sits below that range and includes China. It also builds gradually, so the 2027 effect is closer to half the run-rate figure. On our numbers, the 2027 I&A per procedure line is roughly flat, not down. This is the largest single improvement to the thesis this quarter.

4. Capacity, Not Just Upgrades: The Capital Cycle Broadens

The da Vinci 5 upgrade cycle that dominated Q2 has turned into a capacity cycle. Trade-ins were 150 against 141 a year ago, while total placements rose by 119 units. The CFO tied the shift directly to US procedure demand in benign general surgery.

"And what you saw in this quarter was U.S. net placements increased 41%, and that's a little bit of a change from what we've seen in more recent quarters." — Jamie Samath, CFO

More than 2,000 da Vinci 5 systems are now installed, used by over 18,000 surgeons since launch, and da Vinci 5 systems run at higher utilization than the Xi base. The tiered portfolio widened the funnel: XiR and X installations more than doubled, with XiR at ~$1.2M and X at ~$0.5M.

Assessment: Capacity additions lead procedures by a few quarters. This is the strongest single data point for the view that US growth recovers in 2027, and it was the most under-discussed item on the reaction day.

5. OUS: Europe +83% on Placements, New Countries in 2027

International placements grew 29% to 211, led by Europe at 115, with records in Portugal, Turkey and Austria and 20 installations in Germany. da Vinci 5 placements outside the US rose to 41 from 12 as clearances expanded. Management will accelerate entry into new countries in 2027. It also plans to update its estimate of the long-term soft-tissue opportunity in January.

"Given increasing investments in OUS markets and planned expansion into new geographies, in January, we plan to update our estimate of the long-term opportunity in soft tissue surgery." — Jamie Samath, CFO

Assessment: OUS grew revenue 25.2% and is now 32% of the total. The January TAM update is a catalyst that the July bear case did not include. A larger addressable market, together with lower instrument prices in benign procedures, is the core of the bull case for 2027-2028.

6. China: A Significant Price Cut and Fewer Placements

China is the one region that worsened. The operating environment "remains challenging," procedure growth only matched the corporate average because placements fell in recent quarters, and the charge-code policy change cuts I&A prices significantly from November. Intuitive is still working through the green-channel process for SP and da Vinci 5. It also announced a new I&A manufacturing plant in Penang, Malaysia, from 2028, to serve long-term growth in Asia.

"In China, the charge code policy changes we described last quarter will result in a significant reduction in our I&A prices in that market beginning in November." — Jamie Samath, CFO

Assessment: China is already inside the 3-5% figure, so the price cut adds no new headwind to the model. The direction of travel is negative, however, and domestic competition is the reason. We move the China and macro bear point to EMERGING from CONTAINED.

7. Gross Margin: 68.9% Ex-Refund and a Third Guide Raise

Excluding the refund, non-GAAP gross margin of 68.9% rose 90bp year-over-year on product cost reductions and fixed-overhead leverage. That held through a quarter in which lower-margin systems grew fastest. The FY guide rose to 68.7-69.3%.

"Excluding this benefit, non-GAAP gross margin would have been 68.9%, an improvement of 90 basis points year-over-year." — Jamie Samath, CFO

"We continue to forecast higher input costs in certain areas like freight and semiconductor memory." — Daniel Connally, Head of Investor Relations

Assessment: The gross-margin pillar keeps delivering. The 2027 question is whether cost reductions can absorb the pricing actions as management says. A cost-reduction program already worth ~90bp a year suggests they can, with memory prices the main input risk.

8. Operating Expenses +18% and the 2027 Margin Signal

The figure that changes our 2027 model is not in the release; it came from the CFO's answer on margins. Asked about 2027 profitability, with the Street modeling a flat operating margin, the CFO restated a 35-40% operating-margin framework and noted that the company already runs at 41-42%. In Q3, non-GAAP operating expenses grew 18% on variable compensation, headcount and prototype spending, and R&D grew faster than SG&A.

"And where we are right now, 41%, 42%, we have the capacity to invest." — Jamie Samath, CFO

Assessment: We read this as a signal that 2027 will not bring operating-margin expansion. The investment targets are AI, new platforms and international expansion, all of which we think are good for the franchise. We set our FY27 operating-margin assumption at ~40%, from a FY26 run-rate near 40.8%. This is a new bear point. If the January guide implies a margin well below 40%, it becomes the main bear point.

9. The $450M Antitrust Settlement

Intuitive settled the consolidated class action on third-party remanufacturing and servicing of da Vinci instruments for a one-time $450M plus agreed injunctive relief, with no admission of liability. The charge sits in Q3 SG&A ($347M after tax, $0.99 per share). The settlement needs preliminary and final court approval, which management does not expect until next year.

"We believe that this no-fault settlement provides certainty for both our customers and Intuitive and maintains our ability to advance the safety, quality and security of our products." — David Rosa, CEO

Assessment: $450M is about 0.3% of the market value and less than two months of free cash flow at the nine-month rate. In return, it removes a five-year-old case. The terms of the injunctive relief were not disclosed. That is the item to read when the court filing is public, because it defines how far remanufacturers can compete with the instruments that the extended-use program now discounts.

10. A $2.94B Buyback at $377

Intuitive repurchased 7.8M shares for $2.94B in Q3: 3.6M in July at an average of $364.74 and 4.2M in August at $387.71, with none in September. The average was $377.01. About $1.8B of authorization remains. Cash and investments fell to $6.80B from $8.6B, and non-GAAP other income guidance came down with it. Nine-month operating cash flow was $3,197.0M and capital expenditure $329.0M, for free cash flow of about $2.87B, up 63%.

"Cash generated from operating activities was more than offset by stock repurchases of $2.9 billion at an average price of $377 per share and capital expenditures of $113 million." — Jamie Samath, CFO

Assessment: In July we noted that the company had bought stock at $439 in Q2 just before the shares fell to $345. This time it bought aggressively near the lows, and the stock now sits about 20% above the purchase average. That is the strongest sign so far that management agreed with the July sell-off thesis. The nine-month cash-flow figure needs one caution: it includes a $631.8M increase in other liabilities, which most likely carries the unpaid $450M accrual. Free cash flow will be about $450M lower in the period when the settlement is paid.

11. Pipeline: GI Clearance, Telesurgery by 2028, AI With Restraint

The pipeline moved on several fronts. The FDA cleared Intuitive's foundational, noncommercial flexible robotic endoscope for the GI tract in August, only weeks after the July submission. da Vinci 5 gained clearances for surgeon-initiated tool eject and multi-arm targeting, plus an integrated handheld endoscope. A cavitational ultrasonic aspirator for liver and pancreas surgery is under review. In Europe, CE marks arrived for Force Feedback instruments, da Vinci 5 cardiac use and SP transvaginal gynecology. Management expects several telesurgery clearances in H1 2028 and now sizes the line-of-sight cardiac opportunity at 300,000-400,000 procedures a year in cleared regions.

"Telepresence on da Vinci 5 serves as a foundation for our efforts in telesurgery, where we expect several regulatory clearances in the first half of 2028." — David Rosa, CEO

"AI-controlled motion in surgery has the potential to improve efficiency and outcomes, but it is early and must earn the confidence of regulators, surgeons, care teams and patients before we deploy it at scale." — David Rosa, CEO

Assessment: None of this is in near-term numbers, and that is the point. The pipeline adds revenue per procedure (ROSE, EBUS, hyperspectral imaging), new indications (cardiac, GI) and new sites of care (telesurgery, ASC). This is part of what the reinvested margin will fund.

12. The ASC Channel and the Modular Challenge

The ambulatory surgery center push is real but early. ASCs carry a little under 10% of US soft-tissue surgery, about 70% of that volume runs through ASCs affiliated with existing hospital systems, and Intuitive's penetration is low. Intuitive installed 18 ASC systems in Q3, 15 of them XiR, and the last two quarters together exceed its ASC placements over almost the prior three years. Two competitors are expected to offer modular systems in the ASC, and management rejected the idea that it needs one.

"And we continue to believe that a cart-based architecture consistent with da Vinci is the best option." — David Rosa, CEO

Assessment: The ASC is where the pricing actions, XiR and the benign-procedure evidence base (the new benign COMPARE meta-analysis showed 54% lower odds of conversion to open than laparoscopy) work together. Competition will arrive first in this channel, and the 2027 pricing actions are Intuitive's pre-emptive answer.

Analyst Q&A Highlights

Whether the US Slowdown Is a Lull or a New Rate

The first question framed the whole call. It noted that US growth was stable on a two-year basis but the lowest single quarter since COVID, and asked whether innovation and pricing could reaccelerate US procedures as early as next year. Management answered with strategy rather than a forecast. It pointed to customers' own clinical and economic dashboards, the pricing actions, and the CFO's four drivers: capacity, ASCs, cardiac and breast, and new indications.

Q: "So Jamie or Dave, U.S. da Vinci procedure growth was stable on a stack 2-year basis, but the 10% growth in the quarter was the lowest we've seen since COVID. Shipments were strong, and it sounds like you have a ton of innovation and the extended use program is coming. So are we seeing a temporary lull in U.S. da Vinci procedure growth and the innovations and the pricing actions will help accelerate U.S. da Vinci procedures as soon as next year?"
— Larry Biegelsen, Wells Fargo

A: "I understand investor intention on the U.S. kind of growth over the last several quarters. There's 4 things that we're focused on that we're driving, maybe just to add some color. First is adding capacity, particularly to support the benign general surgery growth. And what you saw in this quarter was U.S. net placements increased 41%, and that's a little bit of a change from what we've seen in more recent quarters."
— Jamie Samath, CFO

Assessment: Management did not say "reaccelerate next year," and that restraint is the right posture before the January guide. The capacity data point was the most concrete answer on the call. The rest was a multi-year argument, which does not settle the 2027 debate.

How the Pricing Actions Flow Through the P&L, and Whether Volume Responds

A follow-up on the extended-use program asked about timing, stocking effects, the margin flow-through and the expected volume response. The answer covered all of it: modest stocking volatility, a modest gross-margin effect offset by cost reductions, and what the CFO called "relative confidence" in elasticity, based on the 2020 program's data.

Q: "How do we think about necessarily the time lines? Will there be any stocking ahead of the implementation of this? And how do we think about it down the P&L, both from a gross and operating margin? If I could add one more there. Last program, you did have a price elasticity benefit on volumes. How are you thinking about volumes in response to the pricing actions?"
— Robert Marcus, JPMorgan

A: "In terms of the impact on gross margin, I would say that it would be a modest impact on gross margin that we'll look across '27 to offset with the cost reduction programs that we have in play. ... We have looked back at the first EUP program that we did in 2020 and our data supports the existence of elasticity. ... That doesn't obviously turn on immediately in 2027, but over time."
— Jamie Samath, CFO

Assessment: This is the most important P&L disclosure after the 3-5% figure itself. The gross-margin effect is small and will be offset, so the pricing actions are mostly a revenue-growth question, not a margin question. The time lag on elasticity means 2027 carries the cost before the volume benefit arrives.

When the Full 3-5% Arrives

A direct question on implementation timing drew a country-by-country schedule that pushes the full effect to the end of 2027.

Q: "On the EUP, how long will it take you to fully implement the program, meaning when do you expect to see the 3% to 5% gross impact on revenue per procedure?"
— Jayson Bedford, Raymond James & Associates

A: "It will be country by country. The first is the U.S. As I said, that submission is in process. So we'd expect to start to roll that out sometime later in Q1, depending on obviously when we get clearance. Europe, it would be next, and that's not until the second half of '27. ... So I don't think we get to the full impact until the end of the year, frankly."
— Jamie Samath, CFO

Assessment: A late-Q1 US start and an H2 European start mean the 2027 average effect is well below the run-rate figure. Investors who apply 3-5% to all of 2027 will overstate the headwind. China, in effect from November, is the only piece that hits Q4 2026.

Force Feedback and the Other Offsets

Questioners asked about the size of the offsets left out of the 3-5%, starting with Force Feedback adoption. The answer included three numbers: Force Feedback is in about 8% of da Vinci 5 cases, SP carries higher I&A per procedure, and da Vinci 5's integrated insufflation adds about $100 per procedure in the ~85% of cases that use it.

Q: "So I would love just any update on force sensing instrumentation. Where is adoption today? What percentage of procedures are being done with force sensing?"
— Adam Maeder, Piper Sandler

A: "In terms of adoption, this quarter, about 8% of da Vinci 5 cases involve Force Feedback. ... And on da Vinci 5, because of the integrated insufflation -- when integrated insufflation is used, which is about 85% of the time, there's an additional about $100 per procedure for the tube sets that connect to the insufflator. So those 3 can drive offsets in terms of the 3% to 5%, and they generally would be expected to grow at a faster pace than the base I&A."
— Jamie Samath, CFO

Assessment: The insufflation figure is the most useful new data point for the model. About $100 on ~85% of da Vinci 5 cases is roughly a 5% lift to I&A per procedure on those cases. With da Vinci 5 at just over a quarter of US procedures, that is worth only about 1% of blended US I&A per procedure today, but it grows with da Vinci 5's share. Force Feedback at 8% is slow, and the evidence base will decide it.

The 2027 Operating-Margin Question

The last question of the call produced its most important forward signal. Asked what else might affect continued margin expansion, management restated a 35-40% range and said it has the capacity to invest from the current 41-42%.

Q: "Street is modeling operating margin flat next year. So while I appreciate you don't really want to get into '27 in detail right now, you talked about offsetting the gross margin headwind from extended use. Are there any other considerations that we should take into account as we think about profitability and your ability to continue to expand margins here going forward?"
— Chris Pasquale, Barclays

A: "I think what we've said for some time now is kind of the range of where we'd expect to be on operating margin is between 35% and 40%. ... And where we are right now, 41%, 42%, we have the capacity to invest. And so as we finish our planning process, then we'll evaluate that carefully. I'm not ready to say what we'll do on operating expenses."
— Jamie Samath, CFO

Assessment: This was a soft push against the Street's flat-margin model. It does not commit to a cut, but the direction is clear: management's stated lean is to invest. We model ~40% for 2027 and treat a lower January guide as the main downside risk to our estimates.

The ASC and the Modular Competitor

A question on the ASC opportunity asked whether a competitor's move toward a modular ASC system means Intuitive needs one. Management said no: it has tested modular and table-mounted designs over 30 years and prefers the cart.

Q: "But related to that, maybe you can touch on now just with the Stryker CMR news, we have 2 competitors likely offering modular systems in the ASC. How do the competitive dynamics play in there? Does Intuitive need a modular offering of some kind?"
— Frederick Wise, Stifel

A: "And so if you -- we believe that it is not required to have a modular type of architecture to serve the needs of the customer in these segments where they are doing benign procedures and maybe increasingly complex procedures over time. And so I think we are well positioned with our portfolio, the pricing that Jamie described to serve the needs of our customers there and we look forward to earning their first choice."
— David Rosa, CEO

Assessment: The answer was firm, and the XiR price point (~$1.2M) plus volume-based instrument pricing gives it substance. Competitive risk in the ASC is a 2027-2028 item. The first test is whether ASC placements recover from 18 this quarter, down from 27 in Q2.

Pipeline Items That Add Revenue per Procedure

A question on pipeline items that could lift revenue per procedure drew a list from management: Ion's ROSE and EBUS programs, advanced visualization including hyperspectral imaging of fluorescent molecules, and AI features.

Q: "And as we're looking at the pipeline, if there's anything you'd like to point to or what could be coming on AI use cases or imaging things or even anything that's interesting on the GI robot or lung cancer that could be helpful for investors at this point."
— Travis Steed, Bank of America

A: "And so we have multiple programs going there with advanced visualization technology around hyperspectral imaging of fluorescent molecules and some AI features that we do think will bring that incremental value, and we're going to be able to add some revenue per procedure as a result."
— David Rosa, CEO

Assessment: Management is building a second offset to price, one that charges for innovation as it cuts price in benign procedures. It is credible but has no timing, and none of it is in our 2027 numbers.

What the Settlement Means for Customers

A question on the settlement asked what it means in practice and whether remanufacturing has been a real headwind. Management described a defined framework for working with customers on third-party instruments and service, but did not size the remanufacturing effect.

Q: "I guess just wondering what this practically means for your customers and how they move on from that. And if you could just talk about remanufacturing in general and whether that's been any kind of real headwind."
— Matthew Taylor, Jefferies

A: "Yes. Just to add briefly, I think the resolution really strengthens our customer relationships, and it just provides a defined framework for how we work together on instruments and servicing."
— Gary Loeb, Chief Legal and Compliance Officer

Assessment: The question about remanufacturing as a headwind went unanswered. We read the settlement together with the extended-use program: longer-life instruments at lower prices compete with remanufacturers on price, under whatever injunctive framework the court approves.

What They're NOT Saying

1. The 2027 operating-expense plan: Deferred to January, with a clear lean toward investment. Until it is set, 2027 EPS estimates carry the widest range in our coverage of this name.
2. The US bariatric decline: The 10-Q says US bariatric procedures fell at a low double-digit rate, worse than Q2's high-single-digit decline. The call did not mention bariatric volumes at all, apart from the clinical study.
3. The size of the China price cut alone: Management called it "significant" and included it in the 3-5% figure, but gave no separate figure and no China share of I&A. The bull case therefore cannot isolate how much of the 3-5% is a one-country policy cut and how much is strategy.
4. How large the elasticity is, and when: Management expressed "relative confidence" in elasticity from the 2020 data but gave no volume response figure. It also said elasticity "doesn't obviously turn on immediately in 2027."
5. Free cash flow: The release has no cash-flow statement, and the call did not mention free cash flow, which it did in July. The 10-Q shows nine-month free cash flow of ~$2.87B, which includes the unpaid settlement accrual inside other liabilities.
6. The injunctive terms of the settlement: The release calls it "mutually agreed injunctive relief" without detail, and those terms define the remanufacturing channel.
7. Any number for Medicaid or 340B exposure: These were added to the watch list without a size, the same pattern as the ACA attribution in July.

Market Reaction

• Pre-print setup: ISRG closed at $438.00 on October 20, up 26.8% from the $345.42 close after our July note and 31.9% above the $332.02 closing low of July 23. It was still down 22.7% year-to-date, against +12.7% for the S&P 500, and down 4.5% over twelve months. It had gained 11.4% in the trailing 30 days, so the stock entered the print with a recovery already priced in.
• After hours (October 20): The shares fell about 7% as investors focused on the 10% US procedure figure, the price cut and the settlement charge.
• Reaction session (October 21): The stock opened at $402.50 (-8.1%) and hit a low of $398.99. It closed at $428.12, down 2.3% (-$9.88), having recovered 72% of the opening gap. Volume was 4.8M shares, 2.1x the 30-day average. The S&P 500 rose 0.6%, while large-cap med-tech peers fell 1.7-2.3%.
• Follow-through: ISRG gained 3.7% on October 22 to $443.85 and 1.9% on October 23 to $452.29, 5.6% above the reaction close. Since our July 17 note the stock is up 30.9%, against +2.2% for the S&P 500.

Sell the Headline, Buy the Detail. The after-hours drop priced the three headline items: the slowest US growth since COVID, a price cut and a $450M charge. The session then repriced the detail behind them, and the 72% recovery from the open says which reading won. The 3-5% figure came in under the range the Street had been using, and the US slowdown had been flagged in July and sits on a flat two-year stack. A capital beat of this size is hard to reconcile with a demand problem. The settlement is a one-time item that ends a long case.

The Peer Tape Mattered. ISRG's -2.3% close was in line with large-cap med-tech on the day (peers fell 1.7-2.3%), so on a relative basis the print was close to neutral by the end of the session. The 3.7% gain on October 22 matched a peer rally of 3.2-3.8% on a day the S&P 500 fell 1.2%. The cleaner signal came on October 23: ISRG rose another 1.9% while peers were flat to down 1.4% and the S&P 500 fell 0.5%. Most sell-side targets rose, though two firms cut theirs. The market treated Q3 as confirmation that the July sell-off was overdone, not as a second leg down.

What Is Now Priced. At $452.29 the stock has recovered most of the de-rating we argued was excessive in July. It trades at ~39.5x our FY26 estimate and ~35.5x FY27, against ~32x FY26 after the July sell-off. The easy part of the recovery is over. From here the stock needs the January guide to confirm that 2027 procedure growth stabilizes in the low-to-mid teens and that margin reinvestment stays moderate.

Street Perspective

Debate: Is 10% the US Trough or the New Run-Rate?

Bull view: The 10% sits on the year's hardest comparison, the two-year stack has held at ~26%, US net placements grew 41%, and da Vinci 5 already carries more than a quarter of US procedures at higher utilization. As the comparisons ease and the added capacity fills, US growth returns to the low-to-mid teens in 2027.

Bear view: Reported US growth has fallen three quarters in a row (14%, 12%, 10%). The watch list has grown from ACA to Medicaid and 340B, bariatric declines are deepening, and the largest installed base in surgery will compound more slowly. A stacked-basis argument is what management offers when the reported number is going the wrong way.

Our take: The bull has the better evidence for now, chiefly the capacity build, but the bear is right that reported growth is what investors pay for. Q4 is the test: on a 15% comparison, US growth near 11% supports the stack argument, and a figure below 10% breaks it. We position for the former and size for the risk of the latter.

Debate: Is the Price Cut an Investment or a Giveaway?

Bull view: This is Intuitive's standard playbook: lower the price of the instrument to expand the market. The 2020 program produced measurable elasticity. The 3-5% is smaller than in 2020, it is phased, and it is aimed at benign OUS and ASC procedures where cost is the barrier. The mix offsets alone could neutralize it.

Bear view: Some of the 3-5% is not a choice. China's cut is policy, and the timing follows competitive entry into the ASC and distributor markets. Price cuts made under competitive pressure rarely produce the elasticity that strategic ones do, and 2027 bears the cost before any volume benefit.

Our take: Mostly an investment, partly defensive. The size is manageable either way. With the phasing and the insufflation and SP offsets, we model I&A per procedure flat in 2027, which leaves I&A growth tied to procedure growth.

Debate: Margin Expansion or Reinvestment in 2027?

Bull view: Gross margin keeps rising, the price cut's margin effect is offset by cost reductions, and at a 41-42% operating margin there is room to invest heavily in AI, telesurgery and new countries while still compounding EPS in the low teens.

Bear view: Management has told the Street that its framework is 35-40% and that it sits above it. A step down toward 39% in 2027, together with slower revenue growth as pricing bites, would leave EPS growth in high single digits. That is not consistent with a mid-30s multiple.

Our take: We model ~40% in 2027, a modest step down that still gives ~11% EPS growth. A January guide that implies 38-39% would cut our FY27 estimate by ~$0.30-0.60, the largest single risk to our base case.

Debate: After a 31% Rally, Is There Upside Left?

Bull view: Estimates are rising: this quarter alone added ~6% to FY26 EPS. The multiple is still below the mid-40s the stock held before this year's growth scare, and January brings a larger TAM estimate. The recovery has room to run.

Bear view: The de-rating trade is done. At ~35x FY27 for ~11% EPS growth, with a price cut and margin reinvestment ahead, the stock now needs a reacceleration it may not get, and the January guide is more likely to be cautious than generous.

Our take: The upside is narrower but still positive. Our base case offers ~13% from Friday's close, ahead of what we expect from the S&P 500, and estimate revisions point up. That supports Outperform with Moderate conviction, not more.

Model Update & Valuation Framework

Valuation: We raise the framework to Base $510 / Bull $635 / Bear $345 from $435 / $540 / $305, and roll the anchor forward to FY27 estimates. The base case uses 40x FY27E EPS of $12.75. It assumes US procedures stabilize in the low teens, I&A per procedure stays flat through the price cut, and operating margin settles near 40%. The bull case uses ~48x on $13.25. It assumes the capacity build shows up in a US reacceleration, elasticity arrives early in OUS benign procedures, and January raises the TAM. The bear case uses ~28x on $12.25, which returns the stock to its July 17 post-print close. It assumes US growth falls into the high single digits and January resets the margin toward 38%. From the $428.12 reaction close the base case implies +19%. From Friday's $452.29 close, the base offers +12.8%, the bull +40.4% and the bear (23.7%). On a 25/50/25 weighting the expected value is ~$500, about 10% above the current price. That is positive against our S&P 500 expectation, but much less than the skew in July.

Sensitivity: Each 100bp of 2027 operating margin is worth ~$0.30 of FY27 EPS, or ~$12 a share at the base multiple. Each point of 2027 procedure growth is worth ~$0.10-0.12 of EPS.

Thesis Scorecard Post-Earnings

Overall: Thesis modestly strengthened. The pillar that drove July's sell-off, the unsized price cut, is now sized and smaller than feared. The capital data support the cyclical reading of the US slowdown, and the gross-margin, OUS and TAM pillars all strengthened. Against that, the US line slowed again on a reported basis, China worsened, and a new 2027 margin-reinvestment risk joins the bear list. The franchise is in better shape than in July. The stock, 31% higher, now prices much of that improvement.

Action: Maintain Outperform, base case $510, conviction 6/10. Hold existing positions. We would add on a move back toward the reaction-day low near $400, but not chase above ~$480 before the January guide. We will reassess the rating if the stock reaches the base case without higher estimates, if the FY27 procedure range starts below 12%, or if the 2027 operating-margin plan lands well below 40%.